PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

Drug side effects

ziprasidone Side Effects

The reactions most often reported to the FDA for ziprasidone (also sold as Geodon), with demographics, serious outcomes, and reporting trends.

Data updated 2026-05-15

17,328
FAERS reports

Data from the FDA Adverse Event Reporting System (FAERS), 2004 to 2025. A FAERS report records a temporal association, not proof of cause. See our methodology for how figures are compiled and de-duplicated.

The most commonly reported side effects of ziprasidone come from 17,328 reports to the FDA, broken down here by frequency, patient demographics, and serious outcomes.

This page analyzes 17,328 reports to the FDA Adverse Event Reporting System (FAERS) for ziprasidone (Geodon): the reactions reported most often, who reported them, serious outcomes such as hospitalization, and year-over-year trends. A FAERS report does not prove the drug caused the effect, and report volume tracks how widely a drug is used, not how likely an effect is for any one person. Educational information, not medical advice.

Total Reports

17,328

Reports Mentioning Death

1,171

6.8% of reports — not proof the medicine caused the death

Hospitalizations

4,189

24.2% of reports

Top Indication

Bipolar Disorder

Most Reported Adverse Reactions

WEIGHT INCREASED
1,176
DIABETES MELLITUS
1,003
ANXIETY
875
TYPE 2 DIABETES MELLITUS
859
INSOMNIA
801
DEPRESSION
782
SOMNOLENCE
744
FATIGUE
719
TARDIVE DYSKINESIA
700
TREMOR
686
NAUSEA
673
DIZZINESS
587
FEELING ABNORMAL
587
SUICIDAL IDEATION
568
HEADACHE
554
OBESITY
510
DYSKINESIA
484
DYSPNOEA
483

Who Reports Side Effects

Gender Distribution

Female 9,453 (61%)
Male 5,832 (38%)
Unknown 199

Age Distribution

0-17 782 (9%)
18-44 4,204 (47%)
45-64 3,163 (35%)
65-74 550 (6%)
75+ 225 (3%)

Reporting Trend by Year

2004 2025

Reactions in Death Reports

Top reactions reported in 1,171 reports where death was an outcome. These are voluntarily reported and do not establish causation.

Reaction Reports
COMPLETED SUICIDE 379
DEATH 247
TOXICITY TO VARIOUS AGENTS 152
CARDIAC ARREST 101
CARDIO-RESPIRATORY ARREST 97
RESPIRATORY ARREST 56
MYOCARDIAL INFARCTION 34
SUDDEN DEATH 34
ARRHYTHMIA 33
HYPOTENSION 32
OVERDOSE 30
NEUROLEPTIC MALIGNANT SYNDROME 28
ADVERSE DRUG REACTION 27
COMA 27
BLOOD GLUCOSE INCREASED 26
CONDITION AGGRAVATED 26
RESPIRATORY FAILURE 26
PNEUMONIA ASPIRATION 25
RENAL FAILURE 25

Reactions in Hospitalization Reports

Top reactions in 4,189 reports where hospitalization was an outcome.

Reaction Reports
WEIGHT INCREASED 367
DIABETES MELLITUS 321
DEPRESSION 299
SUICIDE ATTEMPT 277
ANXIETY 271
TYPE 2 DIABETES MELLITUS 254
SUICIDAL IDEATION 247
NEUROLEPTIC MALIGNANT SYNDROME 244
HYPERTENSION 226
DIZZINESS 200
FATIGUE 200
INSOMNIA 197
NAUSEA 197
PSYCHOTIC DISORDER 191
DYSPNOEA 183
OBESITY 179
TOXICITY TO VARIOUS AGENTS 178
HEADACHE 174
OVERDOSE 173

Compare ziprasidone vs acamprosate →

What the FAERS Data Reveals About ziprasidone Side Effects

The FDA Adverse Event Reporting System (FAERS) contains 17,328 voluntary reports linked to ziprasidone and its brand equivalents (Geodon), spanning 2004 through 2025. Of those, 1,171 (6.8%) listed death as an outcome and 4,189 (24.2%) involved hospitalization. The most common indication reported alongside adverse events was Bipolar Disorder.

Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 61% were female and 38% male; age distribution skews toward 18-44, with 4,204 reports in that bracket. The single most reported reaction is weight increased with 1,176 submissions, followed by diabetes mellitus and anxiety.

How to read these numbers

FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice, speak with a licensed clinician about any side-effect concerns.